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Beryllium (Be) is highly toxic to human, induces oxidative stress and leads to Chronic Beryllium Disease (CBD) or 
berylliosis, apoptosis and cancer. In this study, we have investigated the antioxidative and hepatorenal protective potential of 
Spirulina platensis (SP) against beryllium (Be) induced alterations in hepatorenal biochemical parameters, oxidative stress 
and histopathological alterations in rats. Different doses of SP (50, 100, 200 and 400 mg/kg, p.o.) were administered (once a 
day daily for 7 days) against Be(NO3)2 (1 mg/kg, i.p. once a day daily, for 28 days) induced toxic menifestations in female 
Wistar rats. Be decreased GSH, SOD, CAT, G-6-Pase, ALP and ATPase activities and increased TBARS and ACP activity 
in liver and kidney. Be enhanced ALT, AST, bilirubin, uric acid, creatinine, total cholesterol and decreased haemoglobin, 
total protein, sugar in blood. Be deposited in vital organs of rats and altered the histoarchitecture of liver and kidney. 
Different doses of SP showed dose dependent recovery. SP @400 mg/kg showed significant recovery against Be induced 
oxidative stress, maintained hepatorenal function towards normal and reduced beryllium body burden. Results of the study. 
well supported by histopathological observations, conclude that SP possesses hepatorenal protective potential against  
Be induced toxicity in rats. 
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Beryllium (Be) is a light weight metal, possess unique 
chemical and physical properties (high melting and 
boiling points, corrosion resistance, metal hardening 
capacity, high elasticity, etc.). Due to many desirable 
properties, beryllium is continuously used in various 
industries and have wide range of applications with 
increasing demands, such as in medical diagnostics, 
nuclear/fusion reactors, golf clubs, aerospace 
applications, ceramics, electronics and nuclear defense 
and dental prosthesis industries1,2. However, Be exhibits 
wide range of toxic effects on all life forms including 
humans, and is classified as group I carcinogen3-5. Toxic 
effects of Be envisage immunotoxic3, allergic6, 
mutagenic7 and carcinogenic8 action. While the primary 
health concern related to Be is the lung disease (chronic 
beryllium disease or berylliosis), other health issues are 
hepato-, nephro-, neuro- and testicular toxicities5,9-11.  
Majority of studies on Be toxicity focus on 
occupational pathologies5,12 caused by exposure to Be 
dust. However, Be pollution may affect wide 
population groups through other exposure routes5. 
The use of Be-containing rocket fuels results in rapid 
and dense emissions of high Be amounts to the 
environment. Thus, people residing in proximity to or 
working at the launching (and rocket trace) sites may 
be exposed to high amounts of Be through 
transdermal, respiratory, and gastrointestinal routes. 
Thus, the pollution affects a higher number of people 
than those, who are exposed to occupational factors5. 
Be is found accumulated in soils, close to electronic 
waste disposal grounds13, and therefore, also to 
increased environmental exposure, through drinking 
water and diet5. General human population may also 
expose to Be via air, water, diet as well as smoking on 
daily basis14. Workers are exposed to beryllium 
containing dusts during crushing and grinding of ores, 
and to soluble beryllium salts during extraction and 
processing of beryllium and through welding fumes2.  
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Be exposure induced oxidative stress and lung 
inflammation, play an important role in development of 
beryllium induced chronic inflammatory disorders 
(CBD) and apoptosis15. Accumulated data reported that 
antioxidants inhibited beryllium antigen stimulated 
CD4+T-cell proliferation in peripheral blood 
mononuclear cells from CBD patients, suggesting a 
potential therapeutic utility of antioxidant molecules in 
this and similar granulomatous lung diseases8. Exact 
mechanism of Be toxicity still remains to be 
elucidated. Be altered major metabolic pathways of 
iron, protein, lipid and carbohydrate, leads to 
membrane damage of vital organs and altered the 
histoarchitecture of liver and kidney10,11. Be deposited 
in the vital organs and altered the physiological 
efficiency11,16. Be exposed animals showed 
behavioural changes, including increased motor 
activity, aggressive reactions and complete spasticity5. 
Thus, inhibition of beryllium induced oxidative stress 
may be an approach in prevention of Be induced 
hepatorenal diseases. A number of various synthetic 
compounds and some natural products have been tried 
earlier against Be toxicity but they achieve limited 
success9-11,17,18. Thus, there is urgent need for 
alternative treatment to ameliorate Be toxicity that may 
also be applicable to many other toxicants and many 
species. Use of natural products of plant origin, having 
antioxidant potential may be an alternative in treatment 
of beryllium toxicity. In this regard, an interest in using 
Spirulina platensis (SP), a group of blue-green algae, in 
diet has gained attention in recent years. 
SP is a filamentous cyanobacterium microalgae 
with potent dietary phyto-antioxidant, widely used as 
health food in many countries including India. 
Spirulina’s nutritional qualities are truly “one-of-a-
kind” and promoted as ‘the food of the future’ with 
exceptional constituents that contribute to high energy 
levels. SP is rich source of vitamins, minerals, 
protein, carotenoids, phycocyanins, essential fatty 
acids, and other bioactive molecules such as phenolic 
acids, tocopherols, and γ-linolenic acid19. SP has been 
broadly studied in the field of medicine and food 
industry due to its high nutritive value, lack of 
toxicity, and therapeutic effects. Accumulating 
evidences have shown that SP exerts health promoting 
functions, including antioxidant, anti-inflammatory, 
hepatoprotective, anticancer, antimicrobial, strengthening 
immune system, metalloprotective activities, as well 
as positive effects against hyperlipidemia, obesity and 
diabetes19-23. But it’s antitoxic and hepatorenal protective 
potential against beryllium induced hepatorenal toxicity, 
is still unclear. Thus, Spirulina platensis (SP) was 
investigated against beryllium induced oxidative 
stress, hepatorenal dysfunction, beryllium body 
burden and histopathological alterations in rats. 
 
Materials and Methods 
Maintenance of animals and their feeding 
Female Albino rats (Wistar strain) (8-10 weeks old 
having 150 ± 10 g body weight) were randomly 
selected from departmental animal facility. Animals 
were housed under standard conditions (25 ± 2ºC 
temp, 60-70% relative humidity, 12 h photo period). 
Animals were fed on commercially available standard 
animal diet (Pranav Agro Industries Ltd., New Delhi, 
India) and drinking water ad libitum. Animals used in 
this study were treated and cared for in accordance 
with the guidelines recommended by the Committee 
for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA) Chennai, India 
and experimental protocols were approved by 
Institutional Ethics Committee (CPCSEA/501/01/A) 
of Jiwaji University, Gwalior (MP), India. 
 
Chemicals and plant material 
Pure form of SP powder was procured from NB 
Laboratories Pvt. Ltd., Nagpur (Maharashtra), India 
and stored in a desiccator to avoid oxidation and 
thermal decomposition. Beryllium nitrate was 
purchased from Sigma Aldrich Co. USA. All other 
chemicals used in this study, were of pure and 
analytical grade. Kits used for serum biochemical 
estimation were purchased from E-Merck (Germany).  
 
Experiment design and dose preparation 
Beryllium nitrate (35% w/v) was diluted in triple 
distilled water making up doses of 1 mg/2 mL/kg and 
administered intraperitoneally10. SP powder was 
dissolved in triple distil water and administered orally 
with the help of an intragastric rubber catheter. Forty 
two adult female rats were divided into seven groups 
of six animals in each group as follows:Group I, 
negative control (Normal); Group II, Spirulina 
platensis (SP) per se (400 mg/kg, p.o.) once a day, 
daily for last 7 days; Group III, positive control; 
received Be(NO3)2 (1 mg/kg,i.p.) once a day, daily for 
28 days; Groups IV-VII, Be(NO3)2(as in group III) + 
SP 50, 100, 200 and 400 mg/kg p.o., once a day, daily 
for 7 days, respectively. 
 
Processing samples for biochemical analysis  
Twenty-four hr after the last treatment, blood was 
collected by puncturing the retro-orbital venous sinus 
(retro-orbital plexus) under mild anesthesia24. Blood 
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was allowed to clot for 30 minutes at room 
temperature (25ºC), and then the clot was gently 
detached from the wall of the test tubes with the help 
of a thin sterilized needle. The test tubes were 
centrifuged for 20 minutes at 3000 rpm to harvest serum, 
which was stored at 20C until it was analyzed. For 
other assays, the tissues were homogenized with a 
Remi motor homogenizer (RQ-122), using a glass 
tube and Teflon pestle, in different media according  
to the estimation. Tissue homogenates (10% w/v;  
0.15 M KCl) were prepared for lipid peroxidation. 
Homogenates (5% w/v) were prepared in 0.25 M 
sucrose solution for the estimation of reduced GSH 
and in hypotonic solution (0.008% NaHCO3) for 
enzymatic assay. 
 
Blood biochemical analysis 
Serum was used to determine aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT)25, serum protein26 and blood sugar, bilirubin, 
uric acid, creatinine and total cholesterol were 
assessed by kit methods as per instructions provided 
by the company (E-Merck, Germany). Hemoglobin 
was estimated in the blood using Sahli’s apparatus27. 
 
Assessment of tissue biochemical assay 
Fresh tissues of liver and kidney were immediately 
processed to determine lipid peroxidation (LPO)28, 
reduced glutathione (GSH)29, superoxide dismutase 
(SOD)30, catalase (CAT)31, alkaline phosphatase (ALP) 
and acid phosphatase (ACPase)32, adenosine 
triphosphatase (ATPase)33, and tissue protein26. 
Activity of glucose-6-phosphatase (G-6-Pase) was 
determined in liver34. 
 
Determination of beryllium body burden 
Beryllium contents in blood, liver, kidney and 
spleen were determined with atomic absorption 
spectrophotometer (Thermo-Japan) at wavelength  
235 nm according to the Bokowski method35. 
 
Histological observations 
For histopathological study, liver and kidney 
tissues were fixed immediately in Bouin’s fixative 
and paraffin sections of 5 μm thickness were cut. 
Hematoxylin-eosin (HE) stained slides were observed 
under light microscope. 
 
Statistical analysis 
Results are presented as mean ± S.E. of six animals 
used in each group. Data were subjected to statistical 
analysis through one-way analysis of variance 
(ANOVA) taking significance at 5% level of probability 
followed by Student’s t-test taking significance at  
P ≤0.05, P ≤0.01 and P ≤0.00136. Percent protection 
was calculated by the following formula. 
 
% Protection = 1-(D-N/T-N) X 100 [D = Drug,  
N = Normal, T = Toxicant] 
 
Results 
Blood3 biochemistry 
Table-1 represents the toxic manifestations of Be 
and its response to SP administration in various blood 
biochemical indices that include liver and kidney 
function tests. Activities of AST and ALT 
significantly elevated in Be treated rats as compared 
to normal control rats (P ≤0.001). The level of 
bilirubin, uric acid, creatinine and total cholesterol 
were significantly (P ≤0.001) increased in Be treated 
 
Table 1— Efficacy of Spirulina platensis against beryllium induced alteration(s) in blood biochemistry 
 
Treatment 
AST 
(IU/L) 
ALT 
(IU/L) 
T.Cholesterol
(mg/dL) 
T.Bilirubin
(mg/dL) 
Serum protein
(mg/100 mL)
Haemoglobin
(g/dL) 
Glucose 
(mg/dL) 
Uric acid 
(mg/dL) 
Creatinine 
(mg/dL) 
Control 
SP per se 
Be per se 
Be+SP(50 mg/kg) 
% Protection 
Be+SP(100 mg/kg) 
% Protection 
Be+SP(200 mg/kg) 
% Protection 
Be+SP(400 mg/kg) 
% Protection 
ANOVA  
( F-value) 
65.8±3.6 
66.0±3.6 
152.1±8.4C 
143.3±7.9 
10.1% 
128.3±7.0a 
27.5% 
103.2±5.7c 
56.6% 
95.80±5.2c 
65.2% 
 
37.8@ 
47.2±2.6 
47.5±2.6 
126.0±6.9C 
115.0±6.3 
13.9% 
97.2±5.3c 
36.5% 
80.6±4.4c 
57.6% 
68.3±3.7c 
73.2% 
 
49.3@ 
39.1±2.16 
39.4±2.17 
80.4±4.44C 
72.2±3.99 
19.8% 
65.3±3.60b 
36.5% 
55.6±3.07c 
60.0% 
48.3±2.67c 
77.7% 
 
29.1@ 
0.33±0.01
0.34±0.01 
0.76±0.04C
0.68±0.03
18.6% 
0.61±0.03b
34.8% 
0.52±0.02c
55.8% 
0.43±0.02c
76.7% 
 
36.7@ 
32.8±1.18 
32.0±1.76 
24.0±1.32B 
25.6±1.41 
18.8% 
26.8±1.48 
31.8% 
28.8±1.59a 
54.5% 
30.5±1.68a 
73.8% 
 
5.22@ 
14.5±0.80 
14.3±0.79 
11.3±0.62B 
11.7±0.64 
12.5% 
12.2±0.67 
28.1% 
13.4±0.74 
65.6% 
13.9±0.76\a 
81.2% 
 
3.85@ 
107.2±5.9 
106.9±5.9 
69.3±3.83C 
77.2±4.26 
20.8% 
82.8±4.57 
35.6% 
86.1±4.75a 
44.3% 
90.2±4.98b 
55.1% 
 
10.0@ 
1.18±0.065
1.19±0.065 
2.86±0.15C
2.63±0.14 
13.6% 
2.28±0.12b 
34.5% 
1.90±0.10c 
57.1% 
1.63±0.09c 
73.2% 
 
41.7@ 
0.32±0.01 
0.33±0.01 
0.78±0.04C
0.69±0.03 
19.5% 
0.58±0.03c 
43.4% 
0.52±0.02c 
56.5% 
0.42±0.02c 
78.2% 
 
41.0@ 
[Values are mean ± SE from six rats in each group]. P value Be vs. control at A ≤0.05; B ≤0.01; C ≤0.001; P value treatment vs. Be at 
a ≤0.05; b ≤0.01; c ≤0.001 for student’s t test; @significant (analysis of variance) F= P ≤0.05. AST, Aspartate aminotransferase; ALT, 
Alanine aminotransferase; Be, Beryllium; SP, Spirulina platensis crude; T.Bilirubin, Total Bilirubin; and T.Cholesterol, Total Cholestrol]
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rats, whereas serum protein, haemoglobin (P ≤0.01) 
and blood sugar were significantly decreased  
(P ≤0.001) as compared to normal control rats. Post 
treatment of SP showed dose dependent recovery in 
aforesaid blood biochemical variables, and more 
significant recoupment was observed by SP 400 mg/kg 
as compared with Be treated rats, which was confirmed 
by one way statistical analysis using ANOVA. The 
extent of recovery was calculated as percent protection. 
SP 400 mg/kg showed protection in AST (65.2%), 
ALT (73.2%), bilirubin (76.7%), uric acid (73.2%), 
creatinine (78.2%), total cholesterol (77.7%), 
haemoglobin (81.2%), serum protein (73.8%) and 
blood sugar (55.1%) respectively. SP per se treatment 
at doses of 400 mg/kg did not induce any significant 
alterations in serum and blood biochemical variables as 
compared with normal control rats. 
 
Oxidative stress markers 
Table-2 represents Be induced oxidative stress and 
its response to SP administration. Administration of 
Be induced oxidative stress, resulted in elevation of 
LPO (P ≤0.001), reduction in GSH (P ≤0.001,  
P ≤0.01) and higher activities of SOD (P ≤0.001) and 
CAT significantly (P ≤0.001, P ≤0.01) in liver and 
kidney as compared to normal control rats. Post 
treatment of SP showed dose dependent recovery in 
altered oxidative stress markers in liver and kidney. SP 
at doses of 400 mg/kg showed better results in 
alteration of oxidative stress markers more towards 
normal. The extent of recovery by SP 400 mg/kg was 
calculated by percent protection as seen in LPO liver 
(73.1%) and kidney (80.6%), GSH in liver (77.7%) and 
kidney (65.0%), SOD liver (70.6% ) and kidney 
(78.6%), CAT liver (77.6%) and kidney (66.8%) 
respectively. SP per se treatment at doses of 400 mg/kg 
did not induce any significant alteration on oxidative 
stress markers as compared with normal control rats. 
 
Tissue biochemistry 
Tables 2-3 represents Be induced alterations in 
tissue biochemical variables and it’s response to SP 
administration. Administration of Be significantly 
decreased the total protein content (P ≤0.01), the 
activities of ALP (P ≤0.001), ATPase (P ≤0.001) in 
liver and kidney, G-6-Pase (P ≤0.001) in liver and 
significantly increased the activity of acid 
phosphatase (P ≤0.01, P ≤0.05) in liver and kidney. 
Post treatment of SP against Be intoxication showed 
recovery in dose dependent manner in aforesaid 
altered tissue biochemical variables, thus more 
significant recoupment was observed by SP 400 mg/kg. 
The extent of recovery by SP 400 mg/kg was 
calculated by percent protection as in ALP liver 
(77.5%) and kidney (61.5%), ATPase liver (62.9%) 
and kidney (65.5%), G-6-Pase liver (76.0%), ACP 
liver (69.2%) and kidney (77.2%), and protein in liver 
(60.6%) and kidney (68.4%), respectively. SP per se 
treatment at doses of 400 mg/kg did not induce any 
adverse effect on tissue biochemical variables as 
compared with normal control rats. 
 
Determination of beryllium body burden 
Fig.1, A-D represents the effect of SP on Be 
mobilization from different tissues. Be concentration  
 
 
Table 2 — Efficacy of Spirulina platensis on oxidative stress markers and G-6-Pase activity 
 
Treatment 
LPO 
(n moles of  
TBARS/mg protein) 
GSH 
( mole/g) 
 
CAT 
(µ mole H2O2 
/min/mg protein) 
SOD 
(U/mg protein) 
G-6-Pase 
(µmoles 
pi/min/g tissue)
Liver Kidney Liver Kidney Liver Kidney Liver Kidney Liver 
Control 
SP per se 
Be per se 
Be+SP (50 mg/kg) 
% Protection 
Be+SP (100 mg/kg) 
% Protection 
Be+SP(200mg/kg) 
% Protection 
Be+SP (400 mg/kg) 
% Protection 
ANOVA  
( F-value) 
0.24±0.01 
0.25±0.01 
0.91±0.05C 
0.73±0.04b 
26.8% 
0.62±0.03c 
43.2% 
0.51±0.02c 
59.7% 
0.42±0.02c 
73.1% 
 
73.1@ 
0.47±0.02 
0.49±0.02 
1.35±0.07C 
1.12±0.06b 
26.1% 
0.93±0.05c 
47.7% 
0.78±0.0c 
64.7% 
0.64±0.0c 
80.6% 
 
54.7@ 
7.8±0.43 
7.7±0.42 
5.1±0.28C 
5.8±0.32 
25.9% 
6.3±0.34 
44.4% 
6.8±0.37b 
62.9% 
7.2±0.39b 
77.7% 
 
8.64@ 
6.9±0.38 
6.8±0.37 
4.9±0.27B 
5.3±0.29 
20.0% 
5.9±0.32 
50.0% 
6.0±0.33a 
55.0% 
6.2±0.34a 
65.0% 
 
5.74@ 
68.2±3.7 
68.0±3.7 
44.5±2.4C 
49.9±2.7 
22.7% 
53.8±2.9 
39.2% 
58.7±3.2b 
59.9% 
62.9±3.4b 
77.6% 
 
9.41@ 
65.6±3.6 
65.4±3.6 
46.3±2.5B 
52.6±2.9 
32.6% 
55.8±3.0 
49.2% 
57.6±3.1b 
58.5% 
59.2±3.2b 
66.8% 
 
5.53@ 
64.3±3.5 
63.9±3.5 
39.1±2.1C 
43.9±2.4 
19.0% 
47.6±2.6 
33.7% 
52.7±2.9b 
53.9% 
56.9±3.1b 
70.6% 
 
12.9@ 
60.3±3.3 
60.0±3.3 
38.8±2.1C 
44.6±2.4 
26.9% 
47.5±2.6 
40.4% 
52.0±2.8b 
61.3% 
55.7±3.0b 
78.6% 
 
9.55@ 
7.2±0.39 
7.0±0.38 
4.28±0.23C 
4.76±0.26 
16.4% 
5.1±0.28 
28% 
5.9±0.32b 
55.4% 
6.5±0.35c 
76.0% 
 
14.5@ 
[Values are mean ± SE from six rats in each group]. P value Be vs. control at A ≤0.05; B ≤0.01; C ≤0.001; P value treatment vs. Be at 
a ≤0.05; b ≤0.01; c ≤0.001 for student’s t test; @significant (analysis of variance) F= P ≤0.05. Be, Beryllium; CAT, Catalase; G-6-Pase, 
Glucose-6-phosphatase; GSH, Reduced Glutathione; LPO, Lipid peroxidation; SOD, Superoxide dismutase; SP, Spirulina platensis crude] 
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Table 3 — Efficacy of Spirulina platensis against beryllium induced alteration(s) in enzymatic activities and total protein 
 
Treatment 
ALP 
(mg Pi/100 g/h) 
ACP 
(mg Pi/100 g/h) 
ATPase 
(mg Pi/100 g/min) 
Total Protein 
(mg/100 mg tissue) 
Liver Kidney Liver Kidney Liver Kidney Liver Kidney 
Control 
SP per se 
Be per se 
Be + SP(50 mg/kg) 
% Protection 
Be+SP(100 mg/kg) 
% Protection 
Be+SP(200 mg/kg) 
% Protection 
Be+SP(400 mg/kg) 
% Protection 
ANOVA  
( F-value) 
70.2±3.8 
69.9±3.8 
30.2±1.6C 
38.4±2.1 
20.5% 
44.2±2.4a 
35.0% 
55.6±3.0c 
63.5% 
61.2±3.3c 
77.5% 
 
31.9@ 
2451±135 
2446±135 
1235±68.2C 
1578±87.2 
28.2% 
1680±92.8a 
36.5% 
1879±103c 
52.9% 
1984±109c 
61.5% 
 
20.9@ 
185±10.2 
189±10.4 
250±13.8B 
238±13.1 
18.4% 
225±12.4 
38.4% 
216±11.9 
52.3% 
205±11.3a 
69.2% 
 
4.92@ 
196±10.8 
200±11.0 
246±13.5A 
230±12.7 
32.0% 
222±12.2 
48.0% 
215±11.8 
62.0% 
207.4±11.4a 
77.2% 
 
2.58NS 
2340±129 
2330±128 
1260±69.6C 
1478±81.7 
20.1% 
1678±92.7a 
38.7% 
1856±102c 
55.1% 
1940±107c 
62.9% 
 
18.4@ 
2325±128 
2312±127 
1350±74.6C 
1540±85.1 
19.4% 
1710±94.5a 
36.9% 
1870±103b 
53.3% 
1989±109c 
65.5% 
 
14.8@ 
15.2±0.84 
15.0±0.82 
11.9±0.65B 
12.4±0.68 
15.1% 
12.8±0.70 
27.2% 
13.5±0.74 
48.4% 
13.9±0.76 
60.6% 
 
3.39NS 
15.4±0.85 
15.2±0.84 
11.6±0.64B 
12.0±0.66 
10.5% 
12.4±0.68 
21.0% 
13.4±0.74 
47.3% 
14.2±0.78a 
68.4% 
 
5.02@ 
[Values are mean ± SE from six rats in each group]. P value Be vs. control at A ≤0.05; B ≤0.01; C ≤0.001; P value treatment vs. Be at 
a ≤0.05; b ≤0.01; c ≤0.001 for student’s t test; @significant (analysis of variance) F= P ≤0.05. ACP, Acid phosphatase; ALP, Alkaline 
phosphatase; ATPase, Adenosine triphosphatase; Be, Beryllium; and SP, Spirulina platensis Crude] 
 
 
 
Fig. 1 — (A-D) Protective effect of S. plantensis on Be mobilization in (A) liver; (B) kidney; (C) spleen; and (D) blood. [Values are mean 
± SE from six rats in each group]. P value Be vs. control at A ≤0.05; B ≤0.01; C ≤0.001; P value treatment vs. Be at a ≤0.05; b ≤0.01;  
c ≤0.001 for student’s t test; @significant (analysis of variance) F= P ≤0.05. Abbreviations: Be, Beryllium; SC, Spirulina plantensis crude. 
F variance for ANOVA in Liver=188@; Kidney=188@; Spleen=152@; Blood=194@] 
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in liver, kidney, spleen and blood was significantly 
increased after it’s administration for 28 days  
(P ≤0.001). Post-treatment with SP significantly 
reduced the accumulation of Be in these tissues and 
blood in a dose dependent manner, thus more 
significant protection was observed by SP 400 mg/kg 
(P ≤0.001). ANOVA was found to be significant  
(P ≤0.05) for all the tissues.  
 
Histological observation in Liver and Kidney 
Liver of control rat showed well-formed cord 
arrangement of hepatocytes having prominent nucleus, 
normal appearance of central vein and were separated 
by sinusoids containing Kupffer cells (Fig. 2A, 400X). 
Liver of Be treated rat showed structural loss and 
disintegration of hepatocytes, massive hepatic necrosis, 
hyperchromatia of nuclei, vacuolation in hepatocytes, 
degenerated nucleus and heavy lymphocytic 
infiltration. A considerable number of Kupffer cells are 
observed in the sinusoid walls. (Fig. 2B, 400X). 
Treatment with SP (50 mg/kg), liver showed slight 
improvement in hepatocytes structure and central canal 
with degenerated endothelium (Fig. 2C, 400X). In SP 
(100 mg/kg) treated rats liver showed better cord 
arrangement of well formed hepatocytes, no 
lymphocytic infiltration however, less vacuolation and 
hyperchromatia of nuclei were still present with empty 
sinusoids (Fig. 2D, 400X). In SP (200 mg/kg) treated 
rats, liver showed well-formed polygonal hepatocytes 
with normal nucleus, less vacuolation and well-formed 
hepatic cord arrangement (Fig. 2E, 400X). In SP  
(400 mg/kg) treated rats, liver showed almost normal 
hepatocytes with intact cord arrangement of 
hepatocytes, no vacuolation with normal nuclei  
(Fig. 2F, 400X). 
Kidney of control rats showed well-formed renal 
tubules and Bowman’s capsule with normal glomeruli 
(Fig. 3A, 400X). Kidney of Be treated rats showed 
degenerated glomeruli and capsule wall, constriction 
of glomeruli, hypertrophy of epithelial cells and 
tubular obstruction in most of the tubular lumens, 
losing brush-like edges of tubular cells and heavy 
vacuolation(Fig. 3B, 400X). In SP (50 mg/kg) treated 
rats, kidney showed slight improvement with 
apparently normal renal cortex and better formed 
glomeruli than be per se treatment (Fig. 3C, 400X). In 
SP (100 mg/kg) treated rats, kidney also showed 
slight improvement with better formed uriniferous 
tubule with decrease in hyperchromatia of nuclei  
(Fig. 3D, 400X). In SP (200 mg/kg) treated rats, 
kidney showed well formed Bowman’s capsule and 
uriniferous tubule with decrease in hyperchromatia of 
nuclei (Fig. 3E, 400X). In SP (400 mg/kg) treated 
rats, kidney showed maintained Bowman’s capsule 
with compact glomeruli, well-formed endothelial 
lining of uriniferous tubule with wider lumen and 
intact basement membrane (Fig. 3F, 400X). 
 
Discussion 
Be is highly toxic to living organism. Nearly all 
insoluble and soluble forms of Be are toxic as 
function of the concentration and the exposure degree. 
Toxicological action of Be is due to production of 
ROS, depleted major internal thiol antioxidants and 
results in oxidative stress8,17. In present study, Be 
 
Fig. 2 — (A) Liver of control rat showed well-formed cord 
arrangement of hepatocytes having prominent nucleus and normal
appearance of carnal vein (400X). (B) Liver of beryllium rats
showed structure loss, disintegration of hepatocytes, massive
hepatic necrosis, hyperchromatia and pyknosis of nuclei with
vacuolation in hepatocytes (400X). (C) Liver of SP (50 mg/kg)
treated rats showed slight improvement than Be per se with well-
formed hepatocytes with conspicuous nucleus. Kupffer cells were
also observed (400X). (D) Liver of SP (100 mg/kg) treated rats 
showed better cord arrangement of hepatocytes, no lymphocytic
infiltration however, vacuolation and hyperchromatia of nuclei
were still present (400X). (E) Liver of SP (200 mg/kg) treated rats
showed well-formed cord arrangement of polygonal hepatocytes with
marked nuclei and less vacuolation of hepatocytes (400X).
(F) Liver of SP (400 mg/kg) treated rats showed better formed cord
arrangement of well-formed hepatocytes, no vacuolation, clear central 
vein and few numbers of kupffer cells are seen (400X). 
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induced oxidative stress by depletion of cellular 
reduced glutathione (GSH), increase in lipid 
peroxidation of membrane lipids together with 
inhibition of antioxidant enzymes SOD and CAT 
activities. Metal toxicity due to Be similar to lead, 
aluminium, cadmium, arsenic and mercury generate 
reactive oxygen species (ROS), causes peroxidation 
of membrane lipids and alters the structure and 
functional behaviour of cellular membranes and 
membrane linked enzymes. Be enhanced the 
production of hydroxyl and super-oxide free radicals 
(ROS). These ROS readily induce oxidative damage 
to various biomolecules including DNA, lipids, 
proteins, and lipoproteins and results in damage to 
vital organs (Liver, kidney, heart, brain and lungs). Be 
is considered as an important etiological factor 
implicated in development of several chronic diseases 
such as CBD, neurodegenerative diseases, diabetes 
mellitus, atherosclerosis, arthritis, and cancer8,9,16. 
GSH act as internal antioxidant, protect the 
biological membrane from oxidative damage and help 
in protection of vital organs of the body. Depleted 
GSH, SOD and catalase activities and increased 
TBARS in lipid peroxidation after Be intoxication 
indicated the failure of the antioxidant defence 
mechanism. Antioxidants are the compounds which 
bind with free radicals and neutralise their effects. 
Some of the antioxidants have been proven to be 
effective in preventing beryllium induced toxicity in 
many previous interventions8-11,14-18. SP is a potent 
antioxidant, has been reported earlier in amelioration 
of toxic manifestations induced by chemotherapeutic 
agents, some metals as well as pesticides19,21,23. SOD 
and catalase are the cellular major antioxidant 
enzymes, play an important role in elimination of 
ROS and act as the key component of cellular defence 
mechanism. These antioxidant enzymes depend on 
various essential trace elements (bivalent metal ion) 
and prosthetic groups for proper molecular 
organization and enzymatic action. Be is divalent 
metal ion, may bind to the enzymatic active site and 
inhibited enzymatic action. Decreased SOD and 
catalase activity in Be toxicity reflects decrease in 
mRNA expression of these two antioxidant 
enzymes10. Treatment with SP induced SOD and CAT 
activity may be due to increase in mRNA expression 
of these two antioxidant enzymes and inhibition of 
ROS decrease in lipid peroxidation of liver and 
kidney. Previous study reports that aqueous extract of 
SP and C-phycocyanin are known for its anti-oxidant 
and anti-inflammatory activities22. Due to its better 
antioxidant potential, SP quenches free radicals and 
maintains the antioxidant pool inside the cellular 
environment as also evidenced by previous studies 
against various toxic compounds20-22.  
Liver is a target organ of various xenobiotics and 
major site of metabolism whereas kidney acts as drug 
and xenobiotic excretion. A toxic effect of chemicals, 
drugs and xenobiotic usually appears primarily in 
liver and kidney. After intraperitoneal administration 
of Be and its salts, Be enters in to blood circulation 
and transported as Be-protein complex primarily to 
liver and then rest of vital organs of rats. Thus, 
significant amount of beryllium deposited in vital 
 
Fig. -3 — (A) Kidney of control rats showed well-formed renal tubules
and Bowman's capsule with normal glomeruli (400X). (B) Kidney of 
beryllium treated rats showed degenerated glomerulus and capsule
wall, constriction of glomeruli, tubular obstruction in the tubular
lumen with tubular hypertrophy and heavy vacuolation (400X). 
(C) Kidney of SP (50 mg/kg) treated rats showed better formed
glomeruli than be per se (400X). (D) Kidney of SP (100 mg/kg)
treated rats showed distinct renal tubules with well-formed 
Bowman's capsule and compact glomeruli (400X). (E) Kidney
of SP (200 mg/kg) treated rats showed well-formed tubules with
wider lumen, maintained Bowman's capsule with glomeruli
(400X). (F) Kidney of SP (400 mg/kg) treated rats showed
maintained Bowman's capsule with compact glomeruli, well-
formed endothelial lining was noted. The proximal and distal
tubules were well organized with intact basement membrane
(400X). 
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organs. Liver act as a primary elimination route of Be 
and occupy maximum amount of beryllium in rats5. 
Be produces ROS, leads to hepatocytes membrane 
damage and interrupted liver function thus 
transaminases leak out in to blood circulation and 
increase it’s level higher than normal. In histological 
sections, Be degenerated hepatocytes membrane, 
disturbed cord arrangement of hepatocytes and heavy 
vacuolation, indicates the pro-oxidant effect of Be. 
Treatment with SP showed dose dependent recovery 
in histoarhitecture of liver and prevented the 
membrane damage thus the level of serum 
transaminases returns back towards normal. 
Hyperbilirubinaemia indicated impaired liver 
function, rise significantly with Be intoxication, this 
may be due to more destruction of RBCs, thus 
hemoglobin level decreases and catabolism of free 
hemoglobin results in more production of bilirubin. 
SP is a rich source of minerals, vitamins and 
antioxidants, neutralizes Be induced ROS and showed 
membrane stabilizing effect by improving liver 
function. C-Phycocyanin present in SP, found to be 
effective against free radical-induced cellular 
transformation; inhibit cytochrome P450-mediated 
reactions involved in the formation of reactive 
metabolites of the hepatotoxins37. The antioxidant  
and hepatoprotective property of SP is due to  
their presence of selenium, gamma-linolenic acids,  
β-carotene, xanthophylls, zeaxanthin, echinenone, 
cryptoxanthin, phycocyanin19,21,22, and vitamin E and 
C working individually or in synergy. SP decreases 
the amount of Be deposited in the vital organs, it may 
be due to binding of divalent Be+2 with the compound 
present in SP and help in their excretion. This may be 
due to SP’s chlorophyll and phytonutrient contents 
which shows cleansing property and act as 
detoxifying agent against the toxic substances38. 
Be damage to kidney altered normal kidney 
function by elevation of serum uric acid and 
creatinine. Administration of beryllium nitrate 
showed degeneration of glomeruli as well as 
hypertrophy of epithelial cells of uriniferous tubules. 
The lumen of uriniferous tubules decreases and results 
in obstruction of flow of filtrate, thus the excretory 
material returns back in blood circulation and raise 
the level of uric acid and creatinine in blood. Post 
treatment of SP showed protection against Be induced 
renal injury by maintaining the histoarchitecture of 
kidney and serum biochemical variables towards 
normal. In previous intervention, SP elicited 
significant nephroprotective activity by decreasing 
gentamicin induced higher level of lipid peroxidation, 
creatinine and urea, depleted GSH, SOD activity39. 
Elevation of serum total cholesterol in beryllium 
intoxication indicated severe lipid peroxidation and 
altered lipid metabolism. Lipid peroxidation due to 
ROS increases the supply of non-essential fatty acids, 
which in turn increases cholesterol level in blood and 
tissues. Administration of SP reduced the excess lipid 
peroxidation and prevented the elevated level of 
cholesterol, showing better free radical scavenging 
and hypocholestemic activity of SP. Overall the 
antioxidant and hepatoprotective effect of SP is owed 
to their active constituents such as c-phycocyanins,  
b carotene, vitamins, minerals, proteins, lipids and 
carbohydrates. Previous study also revealed that  
C-phycocyanin, the main ingredient of Spirulina, 
reduces the lipid concentrations through scavenging 
free radicals, inhibiting lipid peroxidation, 
nicotinamide adenine dinucleotide phosphate oxidase 
expression, and increasing the activity of lipoprotein 
lipase, hepatic triglyceride lipase, glycosylated serum 
protein peroxidase and superoxide dismutase19.  
Beryllium decreases blood sugar level and interfere 
with carbohydrate metabolism. Decrease in blood 
sugar provides a signal for glycogenolysis thus 
hepatic glycogen decreases18. The glucose-6-
phosphatase is a SER membrane enzyme involved in 
gluconeogenesis, decreases in beryllium toxicity; it is 
due to binding of beryllium ions to it’s phosphate 
group and with key regulatory enzymes of 
carbohydrate metabolism16. Depleted glucose-6-
phosphatase activity directly reflects the degradation 
of SER membrane, observed by ultra-morphology of 
liver and kidney14. Glucose-6-phosphate is produced 
by breakdown of glycogen, cannot pass the 
hepatocytes membrane until it is converted to free 
glucose by the action of glucose-6-phosphatase in 
liver but due to inhibition of glucose-6-phosphatase 
activity, excess glucose-6-phosphate enters in to 
pentose phosphate pathway and compensate the body 
energy and higher level of glucose-6-phosphate 
induce G6PDH activity in liver and kidney10. Post 
treatment of SP maintains the glucose-6-phosphatase 
activity and blood sugar level more towards normal. 
Previous study reported the metal binding capacity of 
SP40 which may also bind Be+2 (ions) and may 
prevent binding of Be+2 to enzymatic active site thus 
glucose-6-phosphatase activity restored towards 
normal. 
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Be increased the activity of acid phosphatase  
(ACP) in liver and kidney, indicated enhanced  
tissue catabolism and cellular autophagy leading to 
tissue damage. Histopathological observations also 
corroborated this fact with cytoplasmic vacuolation due 
to degeneration of cellular organelles after Be toxicity. 
Treatment with SP showed conspicuous hepatorenal 
protection due to reduction in release of lysosomal 
enzymes and showed better result in restoration of 
ACP activity more towards normal. The ALP and 
ATPase are membrane bound enzymes. Any alteration 
in membrane lipid leads to change in membrane 
fluidity, which in turn alters cellular functions mediated 
by these enzymes. Remarkable depletion in the 
activities of these enzymes was found after beryllium 
toxicity. Be+2 is a potential target for ATP binding and 
that Be+2 out competes Mg+2 for ATP and ADP 
binding. SP is a rich source of minerals containing 
magnesium and zinc which may compete with Be for 
binding to enzymes and help in protection of enzymatic 
activities. Administration of Be decreased total protein 
in serum and tissue indicating protein damaging 
potential of Be which is due to increase in oxidative 
stress or interference with protein biosynthesis. 
Administration of SP showed dose dependent recovery 
may be due to decrease in tissue catabolism by free 
radical scavenging, and supplementation of essential 
amino acids which may help in restoration of proteins 
and maintain enzymatic activities. 
Beryllium does not induce DNA damage at these 
doses; however, Be inhibits the synthesis of nuclear 
proteins and influences the steps leading to DNA 
synthesis and selectively interferes with regulatory 
mechanisms controlling transcriptional events in gene 
expression10. But, it is clear that Be, a bivalent metal 
interferes with biochemical metabolic pathway, 
induces oxidative stress and histopathological lesions 
which lead to hepatorenal abnormalities. 
Our results indicate that SP was remarkably 
effective in amelioration of Be induced oxidative stress 
could be either directly by inhibiting lipid peroxidation 
and scavenging free radicals or indirect through the 
enhancement of the activities of SOD and CAT. These 
properties could be attributed to the high protein 
contents, phenolic compounds with essential fatty acid 
and amino acids, minerals and vitamins, which together 
acts as antioxidants. Therefore, SP could be used to 
prevent and treat hepatic and renal diseases especially 
those induced by oxidative damage. 
 
Conclusion  
The results have demonstrated the antioxidative 
and hepatorenal protective potential of the blue-green 
algae Spirulina platensis (SP) in powder form as 
available in market against Beryllium (Be) toxicity by 
mitigating oxidative stress, decreased Be burden, and 
maintained hepatorenal function with almost normal 
histoarchitecture of liver and kidney. Thus, 
consumption of SP may prove effective in 
amelioration of Be induced hepatorenal toxicity and it 
may also useful in prevention and treatment of Be 
related diseases. Supplementation of SP may also be 
beneficial in manifestation(s) of other toxic 
compounds however, further investigation are 
required. 
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